In the context of the US overdose crisis, improving access to medications for opioid use disorder is urgently needed. The Canadian model of methadone treatment, whereby clinicians can prescribe methadone for opioid use disorder in office-based settings and methadone can be dispensed through community pharmacies, offers a compelling model for adoption in the US. Office-based settings in which methadone is prescribed often adopt a rapid-access model, allowing walk-in appointments and same-day initiation of methadone. Prescribing authorization requirements have been relaxed over the past 25 years to improve access to methadone. This paper summarizes the model of office-based methadone prescribing in Canada, highlighting the regulatory structures, prescribing practices, and interprofessional collaborations that enable methadone treatment in office-based settings. Potential implementation strategies for adopting office-based prescribing in the US are discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271524 | PMC |
| http://dx.doi.org/10.1097/ADM.0000000000000950 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Facilitators and Barriers to adherence to antiretroviral therapy among incarcerated people living with HIV in Iran: insights from a qualitative study.
Harm Reduct J
January 2025
HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Background: Ensuring consistent adherence to antiretroviral therapy (ART) is crucial for effective HIV treatment and achieving viral suppression. Within prisons, the prevalence of HIV is notably high, and incarcerated individuals face an increased risk of transmitting the virus both during and after incarceration. However, facilitators and barriers to ART adherence among these individuals in low- and middle-income countries remain inadequately explored.
View Article and Find Full Text PDFPart 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports.
Pharmacol Res Perspect
February 2025
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Data addressing safety concerns related to potential drug interactions between cannabis-derived products and pharmaceutical medications in the pediatric population are lacking. In this study, we retrieved case reports through a published literature search using PubMed and spontaneous reporting data using the Food and Drug Administration's Adverse Event Reporting System (FAERS) to identify potential cannabis- and cannabinoid-drug interactions in individuals younger than 18 years old. To evaluate the published case reports, we used the Drug Interaction Probability Scale (DIPS), a 10-item questionnaire designed to discern the causal relationship between a potential drug interaction and adverse drug reactions (ADRs).
View Article and Find Full Text PDFAn initial randomized controlled trial of a Combined Medication and Behavioral Activation Treatment (CoMBAT) for people with opioid use disorder.
J Subst Use Addict Treat
December 2024
The Fenway Institute, Fenway Health, Boston, MA, USA; Department of Psychology, University of Massachusetts Boston, MA, USA.
Introduction: Opioid use disorder is a chronic, relapsing disease and a major source of morbidity and mortality in the U.S. Medications for opioid use disorder (MOUD) have been shown to reduce opioid use; however, MOUD maintenance is often suboptimal.
View Article and Find Full Text PDFMedications for Opioid Use Disorder in People Who Inject Substances: Reflection on the Potential Place of Morphine Sulfate as Substitution Treatment? Results of COSINUS Cohort Study.
Subst Use Misuse
December 2024
Centre d'étude des mouvements sociaux (Inserm U1276, /UMR CNRS 8044, /EHESS/Paris), Paris, France.
Background: Opioid Use Disorder (OUD) often provokes dramatic consequences in terms of increased morbi-mortality. Two medications have mainly been worldwide used for OUD (MOUD), buprenorphine and methadone. Recently, however, some reports have highlighted the use of Morphine Sulfate (MS) mainly obtained without a prescription but used as MOUD by opioid users and especially People Who Inject Substances (PWIS).
View Article and Find Full Text PDFDifferential Effects of Prenatal Buprenorphine and Methadone on Postnatal Growth and Gene Expression in the Nucleus Accumbens.
Dev Psychobiol
January 2025
Department of Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA.
Article Synopsis
- Methadone and buprenorphine are used during pregnancy to help women with opioid use disorder, but babies exposed to these medications may experience neonatal opioid withdrawal syndrome (NOWS), affecting their feeding behavior.
- A study involving pregnant female rats showed that offspring exposed to either drug had lower weights compared to those given saline, with buprenorphine offspring maintaining lower weights longer than those exposed to methadone.
- Gene expression analysis indicated that while both drugs had similar effects, methadone-exposed offspring exhibited significantly reduced levels of the gene proopiomelanocortin (Pomc), suggesting different developmental impacts between the two medications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!